Increases of mean fluorescence intensity reflecting surface expression level of αIIbβ3 and CD42b in control cells or treated cells
. | PHA + PMA + act D . | . | PHA + act D . | . | ||
|---|---|---|---|---|---|---|
. | αIIbβ3 . | CD42b . | αIIbβ3 . | CD42b . | ||
| Control cells | 44.4 ± 1.8 | 41.5 ± 3.2 | 46.4 ± 2.1 | 39.8 ± 2.5 | ||
| MV | 518.5 ± 66.7 | 112.6 ± 7.4 | 177.8 ± 14.8 | 100.7 ± 17.8 | ||
| MV + H-89 | 75.2 ± 6.3* | 93.3 ± 8.9† | ND | ND | ||
| MV + KT5720 | 408.4 ± 29.6† | 88.9 ± 5.6† | ND | ND | ||
| MV + cyclopamine | 229.4 ± 44.4* | 85.3 ± 4.6† | ND | ND | ||
| MV + 5E1 antibody | 396.1 ± 41.8† | 91.9 ± 3.1† | ND | ND | ||
| MV + @ Smo | 370.4 ± 61.5‡ | 81.5 ± 3.7† | 134.3 ± 9.5† | 74.08 ± 4.5† | ||
| MV + @ control | 533.3 ± 58.9 | 115.6 ± 11.9 | 229.6 ± 9.2 | 112.6 ± 4.9 | ||
. | PHA + PMA + act D . | . | PHA + act D . | . | ||
|---|---|---|---|---|---|---|
. | αIIbβ3 . | CD42b . | αIIbβ3 . | CD42b . | ||
| Control cells | 44.4 ± 1.8 | 41.5 ± 3.2 | 46.4 ± 2.1 | 39.8 ± 2.5 | ||
| MV | 518.5 ± 66.7 | 112.6 ± 7.4 | 177.8 ± 14.8 | 100.7 ± 17.8 | ||
| MV + H-89 | 75.2 ± 6.3* | 93.3 ± 8.9† | ND | ND | ||
| MV + KT5720 | 408.4 ± 29.6† | 88.9 ± 5.6† | ND | ND | ||
| MV + cyclopamine | 229.4 ± 44.4* | 85.3 ± 4.6† | ND | ND | ||
| MV + 5E1 antibody | 396.1 ± 41.8† | 91.9 ± 3.1† | ND | ND | ||
| MV + @ Smo | 370.4 ± 61.5‡ | 81.5 ± 3.7† | 134.3 ± 9.5† | 74.08 ± 4.5† | ||
| MV + @ control | 533.3 ± 58.9 | 115.6 ± 11.9 | 229.6 ± 9.2 | 112.6 ± 4.9 | ||
Cells were treated with either 5 μg/mL PHA/PMA/act D—generated Hh+ MVs or 10 μg/mL PHA/act D-generated Hh+ MVs, in the absence or in the presence of H89 (150 μM), KT5720 (30 μM), 30 μM cyclopamine, 10 μg/mL 5E1 antibody to Hh, anti-Smo (1:150) or preimmune sera (1:150). Data are from 8 experiments.
P < .001, significantly different from MV-treated cells.
P < .05, significantly different from MV-treated cells.
P < .01, significantly different from MV-treated cells.